Growing Awareness Over Genetic Neurodegenerative Disorders Drives the Huntington’s Disease Therapeutics Market, According to a New Report by Global Industry Analysts, Inc

1629

GIA announces the release of a comprehensive global report on Huntington’s Disease Therapeutics. The global market for Huntington’s Disease Therapeutics is projected to exceed US$1.3 billion by 2020, driven by growing awareness about the disease worldwide and the huge unmet patient needs.

San Jose, California (PRWEB) March 20, 2015

Huntington’s Disease (HD) is a genetic, progressive neurodegenerative brain disorder caused by mutation in the gene coding for ‘Huntingtin’ protein. Current HD therapeutics is limited to symptomatic treatments and there are no treatment options with proven safety and efficacy to slow down disease progression or enhance survival rate. Due to lack of approved medications, the clinical needs of HD therapeutics are largely met with off-label use of conventional anti-epileptics and anti-psychotic drugs. Off-label use of these medications is widespread due to the lack of approved alternatives. Growth in the market is driven by rising prevalence of and awareness about the disease, unmet patient needs, and ongoing research on Huntington’s disease.

Growth in global market value is forecast to benefit from the high cost of the only approved therapy, Xenazine®.Xenazine® represents the only FDA approved drug in the United States indicated for HD and prescribed for the treatment of chorea associated with the disease. The ‘orphan drug’ status of Xenazine® makes the drug expensive. The drug’s generic version, Tetrabenazine has been in use for over three decades in many countries throughout Europe. Successful launch of late stage drugs currently in pipeline has the potential to offer stiff competition to Xenazine® in the future. SD-809 by Auspex Biopharmaceuticals, PBT2 by Prana, RP103 by Raptor, and Teva Pharmaceutical’s Huntexil® represent popular pipeline drugs for HD.

As stated by the new market research report on Huntington’s Disease Therapeutics, the United States represents the largest and the fastest growing market worldwide with a CAGR of 21.6% over the analysis period. In the United States, Huntington’s Disease Parity Act of 2013 successfully waived off the earlier 2-year waiting period for HD patients for gaining eligibility for disability assistance through Medicare and Medicaid.

Major players in the marketplace include Alnylam Pharmaceuticals Inc., Auspex Pharmaceuticals, Inc., Intellect Neurosciences Incorporation, Lundbeck A/S, Prana Biotechnology Limited, Raptor Pharmaceuticals Corp, Sangamo Biosciences, Inc., Teva Pharmaceutical Industries Ltd., Trophos SA, Valeant Pharmaceuticals International, Inc., and Vertex Pharmaceuticals Incorporated.

The research report titled “Huntington’s Disease Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the market, current trends, growth drivers, research pipeline, research breakthroughs, mergers, acquisitions, product launches and other strategic industry activities of major global and regional players. The report provides market estimates and projections in US$ for major geographic markets including the United States, Europe (France, Germany, UK, Spain, and Rest of Europe), and Rest of World.

For more details about this comprehensive market research report, please click here

READ MORE

Source: PRNWeb

Print Friendly, PDF & Email